Capricor Therapeutics
its lead asset Deramiocel (formerly CAP-1002), an allogeneic cardiosphere-derived cell therapy whose benefit in Duchenne muscular dystrophy is believed to work partly through paracrine exosome secretion, has a Biologics License Application now scheduled for FDA Advisory Committee review on July 29, 2026,…
- Country
- United States
- Ticker
- CAPR
cell-therapy
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Exosome therapy & extracellular vesicles | regenerative-personalized | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.